Companies that find new ways to regulate validated targets have a leg up on the competition—both in terms of clinical relevance and partnering potential. For RNA interference (RNAi) firms Acuity Pharmaceuticals and Sirna Therapeutics Inc. , the hope is that this logic holds true, even though their compounds are first-in-class structures not yet seen in the clinic, and therefore not yet proven to have essential drug-like properties.
While RNAi has quickly gained a stellar reputation for its utility as a research tool—in target validation and functional genomics,...







